Gadoversetamide

Gadoversetamide
Clinical data


AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Intravenous
Pharmacokinetic data
Protein binding	Nil
Metabolism	Nil
Biological half-life	80 to 120 minutes
Excretion	Renal
Identifiers
CAS Number	131069-91-5^Y
ATC code	V08CA06 (WHO)
PubChem	CID 6435809
DrugBank	DB00538^Y
ChemSpider	392041^Y
UNII	RLM74T3Z9D^Y
KEGG	D01646^Y
ChEMBL	CHEMBL1200457^N
Chemical data
Formula	C₂₀H₃₄GdN₅O₁₀
Molar mass	661.77 g/mol
SMILES [Gd+3].O=C(NCCOC)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(=O)NCCOC)CC([O-])=O
InChI InChI=1S/C20H37N5O10.Gd/c1-34-9-3-21-16(26)11-24(14-19(30)31)7-5-23(13-18(28)29)6-8-25(15-20(32)33)12-17(27)22-4-10-35-2;/h3-15H2,1-2H3,(H,21,26)(H,22,27)(H,28,29)(H,30,31)(H,32,33);/q;+3/p-3^Y Key:HBEAOBRDTOXWRZ-UHFFFAOYSA-K^Y
^NY (what is this?) (verify)

Gadoversetamide is a gadolinium-based MRI contrast agent, particularly for imaging of the brain, spine and liver.^[1] It is marketed under the trade name OptiMARK.

Notes

↑ "Gadoversetamide Drug Information". Drugs.com. 2000-03-20. Retrieved 2007-03-23.

Contrast media (V08)

X-ray and CT

Iodinated,
Water soluble

Nephrotropic, high osmolar	Diatrizoic acid^# Metrizoic acid Iodamide Iotalamic acid Ioxitalamic acid Ioglicic acid Acetrizoic acid Iocarmic acid Methiodal Diodone

Nephrotropic, low osmolar	Metrizamide Iohexol^# Ioxaglic acid Iopamidol Iopromide Iotrolan Ioversol Iopentol Iodixanol Iomeprol Iobitridol Ioxilan

Hepatotropic	Iodoxamic acid Iotroxic acid Ioglycamic acid Adipiodone Iobenzamic acid Iopanoic acid Iocetamic acid Sodium iopodate Tyropanoic acid Calcium iopodate

Iodinated,
Water insoluble

Non-iodinated

Barium sulfate^#

MRI

Paramagnetic	Gadolinium-based: Gadobenic acid Gadobutrol Gadodiamide Gadofosveset Gadolinium Gadopentetic acid Gadoteric acid Gadoteridol Gadoversetamide Gadoxetic acid Other: Ferric ammonium citrate Mangafodipir

Superparamagnetic	Ferumoxsil Ferristene Iron oxide, nanoparticles

Other	Perflubron

Ultrasound

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Tuesday, April 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.